Q2 2024 EPS Estimates for Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Increased by Analyst

Aclaris Therapeutics, Inc. (NASDAQ:ACRSFree Report) – Equities researchers at William Blair upped their Q2 2024 earnings per share (EPS) estimates for shares of Aclaris Therapeutics in a research note issued to investors on Monday, June 17th. William Blair analyst T. Lugo now forecasts that the biotechnology company will post earnings of ($0.17) per share for the quarter, up from their previous forecast of ($0.23). The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.78) per share. William Blair also issued estimates for Aclaris Therapeutics’ Q3 2024 earnings at ($0.17) EPS, Q4 2024 earnings at ($0.18) EPS, FY2024 earnings at ($0.75) EPS, Q1 2025 earnings at ($0.19) EPS, Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.20) EPS and FY2025 earnings at ($0.75) EPS.

Separately, StockNews.com cut shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, April 2nd. One research analyst has rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $22.25.

Check Out Our Latest Report on ACRS

Aclaris Therapeutics Price Performance

Shares of Aclaris Therapeutics stock opened at $1.13 on Wednesday. The stock has a market capitalization of $80.52 million, a price-to-earnings ratio of -1.04 and a beta of 0.06. The business has a 50-day moving average of $1.17 and a 200 day moving average of $1.16. Aclaris Therapeutics has a 12 month low of $0.59 and a 12 month high of $11.12.

Aclaris Therapeutics (NASDAQ:ACRSGet Free Report) last released its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.04. Aclaris Therapeutics had a negative net margin of 248.28% and a negative return on equity of 61.03%. The firm had revenue of $2.40 million during the quarter, compared to analysts’ expectations of $1.99 million.

Insider Buying and Selling

In other news, major shareholder Braden Michael Leonard purchased 150,000 shares of the firm’s stock in a transaction that occurred on Monday, June 17th. The stock was bought at an average price of $1.13 per share, for a total transaction of $169,500.00. Following the completion of the purchase, the insider now directly owns 11,502,134 shares of the company’s stock, valued at $12,997,411.42. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last ninety days, insiders have bought 1,678,621 shares of company stock worth $1,857,414. Company insiders own 6.40% of the company’s stock.

Institutional Trading of Aclaris Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Vontobel Holding Ltd. boosted its position in shares of Aclaris Therapeutics by 128.8% during the 4th quarter. Vontobel Holding Ltd. now owns 30,268 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 17,040 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Aclaris Therapeutics during the first quarter worth approximately $39,000. SG Americas Securities LLC boosted its holdings in Aclaris Therapeutics by 69.5% in the first quarter. SG Americas Securities LLC now owns 32,843 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 13,461 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Aclaris Therapeutics by 115.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 43,784 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 23,467 shares during the last quarter. Finally, Russell Investments Group Ltd. raised its holdings in Aclaris Therapeutics by 5,265.1% during the first quarter. Russell Investments Group Ltd. now owns 62,772 shares of the biotechnology company’s stock worth $78,000 after purchasing an additional 61,602 shares in the last quarter. 98.34% of the stock is currently owned by institutional investors and hedge funds.

Aclaris Therapeutics Company Profile

(Get Free Report)

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.

Featured Stories

Earnings History and Estimates for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.